Eli Lilly Reports Late-Stage Weight Loss Trial Results for Foundayo and Zepbound
Eli Lilly (LLY) announced positive results from late-stage trials showing that its oral weight loss drug, Foundayo, effectively maintains initial weight loss after patients transition from higher-dose injectables like Wegovy or Zepbound. The findings suggest new treatment flexibility for chronic obesity management and were published in top medical journals.
